Genmab — Juni 2018
-
Forward p/e jævnfør 4-traders er på 25 for 2019.
-
Undskylder stavefejlen er igang på tlf.
-
Company Announcement
Copenhagen, Denmark; June 7, 2018 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 5,305 restricted stock units and 14,714 warrants to employees of the company and two of the company's subsidiaries.
-
-
Kan vi så regne med de bliver solgt i morgen og presser kursen yderligere?
-
God morgen
-
God morgen
-
Subcutaneous Daratumumab Plus CyBorD in Newly-Diagnosed Amyloid Light Chain Amyloidosis - https://www.cancertherapyadvisor.com/asco-2018/daratumumab-cybord-newly-diagnosed-amyloid-light-chain-amyloidosis/article/771775/
-
-
4000 ND a year in the US. Compared to a little more than 30000 in MM (2016) https://www.cancer.net/cancer-types/amyloidosis/statistics
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind